PET Imaging in Bladder Cancer: An Update and Future Direction-Reference-Cited by-同舟云学术

PET Imaging in Bladder Cancer: An Update and Future Direction

Published:2023-04-17 Issue:4 Volume:16 Page:606
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

Zhang-Yin Jules¹^ORCID,Girard Antoine²,Marchal Etienne²,Lebret Thierry³,Homo Seban Marie⁴,Uhl Marine⁵,Bertaux Marc⁴^ORCID

Affiliation:

1. Department of Nuclear Medicine, Clinique Sud Luxembourg, Vivalia, B-6700 Arlon, Belgium

2. Department of Nuclear Medicine, Amiens-Picardy University Hospital, 80054 Amiens, France

3. Department of Urology, Foch Hospital, 92150 Suresnes, France

4. Department of Nuclear Medicine, Foch Hospital, 92150 Suresnes, France

5. Department of Urology and Renal Transplantation, Amiens-Picardy University Hospital, 80054 Amiens, France

Abstract

Molecular imaging with positron emission tomography is a powerful tool in bladder cancer management. In this review, we aim to address the current place of the PET imaging in bladder cancer care and offer perspectives on potential future radiopharmaceutical and technological advancements. A special focus is given to the following: the role of [18F] 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in the clinical management of bladder cancer patients, especially for staging and follow-up; treatment guided by [18F]FDG PET/CT; the role of [18F]FDG PET/MRI, the other PET radiopharmaceuticals beyond [18F]FDG, such as [68Ga]- or [18F]-labeled fibroblast activation protein inhibitor; and the application of artificial intelligence.

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://www.mdpi.com/1424-8247/16/4/606/pdf

Reference83 articles.

1. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort: Under the auspices of the eau-esmo guidelines committees;Witjes;Eur. Urol.,2020

3. Bladder cancer;Kaufman;Lancet,2009

4. Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018;Cumberbatch;Eur. Urol.,2018

5. Staging of bladder cancer;Magers;Histopathology,2019